{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:26:04Z","timestamp":1791951964690,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.ajkd.2025.08.013","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:24:58Z","timestamp":1760743498000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["What\u2019s New in Membranous Nephropathy and How to Incorporate New Antigen Discoveries Into Clinical Practice: A Review"],"prefix":"10.1053","volume":"87","author":[{"given":"Ladan","family":"Zand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.mayocp.2020.11.028","article-title":"A target antigen-based approach to the classification of membranous nephropathy","volume":"96","author":"Bobart","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1053\/j.ajkd.2025.08.013_bib4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.08.013_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.08.013_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.08.013_bib7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.34067\/KID.0002492021","article-title":"Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: commentary","volume":"2","author":"Klomjit","year":"2021","journal-title":"Kidney360"},{"issue":"9","key":"10.1053\/j.ajkd.2025.08.013_bib8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/ckj\/sfad075","article-title":"Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1053\/j.ajkd.2025.08.013_bib9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib13","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.08.013_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.kint.2023.04.006","article-title":"Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1681\/ASN.0000000000000061","article-title":"Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor","volume":"34","author":"Sethi","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.kint.2024.07.031","article-title":"A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry","volume":"106","author":"Vrana","year":"2024","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2025.08.013_bib17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41581-025-00980-z","article-title":"Antigens in membranous nephropathy: discovery and clinical implications","volume":"21","author":"Sethi","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ki.2012.484","article-title":"Glomerular diseases seen with cancer and chemotherapy: a narrative review","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.08.013_bib20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2025.08.013_bib21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJMc1500130","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"372","author":"Godel","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2025.08.013_bib22","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2007.06.003","article-title":"Long-term risk of cancer in membranous nephropathy patients","volume":"50","author":"Bjorneklett","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1681\/ASN.2020081181","article-title":"In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes","volume":"32","author":"Ravindran","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.08.013_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe?","volume":"76","author":"Baker","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2025.08.013_bib26","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.34067\/KID.0004582020","article-title":"Can NSAIDs be used safely for analgesia in patients with CKD?: pro","volume":"1","author":"Barreto","year":"2020","journal-title":"Kidney360"},{"issue":"2","key":"10.1053\/j.ajkd.2025.08.013_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ekir.2023.11.021","article-title":"Target antigens of membranous nephropathy with syphilis infection","volume":"9","author":"Zhang","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1053\/j.ajkd.2025.08.013_bib28","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.2215\/CJN.11180821","article-title":"Time to abandon kidney biopsy to diagnose membranous nephropathy?","volume":"16","author":"Ronco","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.08.013_bib29","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1093\/ndt\/gfaa239","article-title":"Seropositive PLA2R-associated membranous nephropathy but biopsy-negative PLA2R staining","volume":"36","author":"Luo","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/j.ajkd.2022.01.426","article-title":"Clinicopathological characteristics and outcomes of PLA2R-associated membranous nephropathy in seropositive patients without PLA2R staining on kidney biopsy","volume":"80","author":"Luo","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.kint.2025.04.032","article-title":"Phospholipase A2 receptor-positive membranous nephropathy detected by laser microdissection and mass spectrometry in patients negative by immunofluorescence for phospholipase A2 receptor on kidney biopsy","volume":"108","author":"Zand","year":"2025","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.08.013_bib32","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.kint.2021.10.010","article-title":"Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy","volume":"100","author":"Spain","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.08.013_bib33","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.kint.2022.09.001","article-title":"Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy","volume":"102","author":"Kurien","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.08.013_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2024.02.007","article-title":"Anti-neuron-derived neurotrophic factor antibodies in secondary membranous nephropathy caused by syphilis: a case report","volume":"84","author":"Honda","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CN110586","article-title":"Syphilis-associated membranous nephropathy successfully treated with amoxicillin","volume":"96","author":"Hazue","year":"2021","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000364782","article-title":"Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies","volume":"40","author":"Leeaphorn","year":"2014","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12882-024-03632-9","article-title":"Nephrotic syndrome associated with solid malignancies: a systematic review","volume":"25","author":"Liu","year":"2024","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.08.013_bib38","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib39","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ekir.2025.02.011","article-title":"High temperature requirement protein a1-positive membranous nephropathy in a patient with chronic lymphocytic leukemia","volume":"10","author":"Zand","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2025.08.013_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfad175","article-title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","volume":"39","author":"Caravaca-Fontan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib42","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2025.08.013_bib44","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"Van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.08.013_bib45","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"Van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.08.013_bib46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.08.013_bib47","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Long-term outcome of adult patients with membranous nephropathy treated with rituximab","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2025.08.013_bib48","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/ckj\/sfad081","article-title":"The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab","volume":"16","author":"Alberici","year":"2023","journal-title":"Clin Kidney J"},{"issue":"9","key":"10.1053\/j.ajkd.2025.08.013_bib49","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/ckj\/sfad074","article-title":"Therapy of membranous nephropathy: quo vadis?","volume":"16","author":"Glassock","year":"2023","journal-title":"Clin Kidney J"},{"issue":"12","key":"10.1053\/j.ajkd.2025.08.013_bib50","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.08.013_bib51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J Immunol Methods"},{"key":"10.1053\/j.ajkd.2025.08.013_bib52","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.08.013_bib53","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CCO.0000000000000107","article-title":"Obinutuzumab: a new class of anti-CD20 monoclonal antibody","volume":"26","author":"Gagez","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.08.013_bib55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.08.013_bib56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2025.08.013_bib57","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.ajkd.2025.08.013_bib58","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","article-title":"Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy","volume":"9","author":"Su","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib59","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000515087","article-title":"Bortezomib treatment for refractory PLA2R-positive membranous nephropathy","volume":"1","author":"Geara","year":"2021","journal-title":"Glomerular Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib61","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy","volume":"100","author":"Salhi","year":"2021","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.08.013_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib63","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.08.013_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14263","article-title":"A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab","volume":"26","author":"Benoit","year":"2022","journal-title":"Pediatr Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2025.08.013_bib65","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib66","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2023.10.035","article-title":"Complement activation and effector pathways in membranous nephropathy","volume":"105","author":"Kistler","year":"2024","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22134","article-title":"Therapeutic plasmapheresis in idiopathic membranous nephropathy anti-PLA2R-related: a case series","volume":"39","author":"Musone","year":"2024","journal-title":"J Clin Apher"},{"issue":"3","key":"10.1053\/j.ajkd.2025.08.013_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14030249","article-title":"Is there a place for apheresis in the management of idiopathic membranous nephropathy? A report of three cases and literature review","volume":"14","author":"Naciri Bennani","year":"2024","journal-title":"J Pers Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.08.013_bib70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jca.21949","article-title":"Peptide GAM immunoadsorption in anti-PLA2 R positive autoimmune membranous nephropathy. The PRISM trial","volume":"37","author":"Hamilton","year":"2022","journal-title":"J Clin Apher"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625010790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625010790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:26:06Z","timestamp":1766046366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625010790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0272638625010790"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.08.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What\u2019s New in Membranous Nephropathy and How to Incorporate New Antigen Discoveries Into Clinical Practice: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}